PLEASE COMPLETE THIS POSTSURVEY AFTER THE PRESENTATION

Question Title

* 1. Which of the following is a JAK-mediated cytokine active in psoriasis?

Question Title

* 2. How confident are you that you selected the correct response for the previous question?

Question Title

* 3. The results of the phase 2 trial of deucravacitinib (BMS-986165) in psoriasis show which of the following?

Question Title

* 4. Which of the following is correct regarding the theoretical mechanistic safety of TYK2 inhibition compared with JAK inhibitors?

Question Title

* 5. How confident are you that you selected the correct response for the previous question?

Question Title

* 6. Recent data from the POETYK-PSO-1 trial in psoriasis shows deucravacitinib was superior to placebo and which active comparator for PASI75 response at week 16?

Question Title

* 7. Francine is a 43-year-old woman with moderate to severe plaque psoriasis with nail involvement, and psoriatic arthritis involving her peripheral joints. Which of the following is likely to be most beneficial?

T